Plasmacytoid dendritic cells (pDC) rapidly and massively produce type I IFN and other inflammatory cytokines in response to foreign nucleic acids, thereby indirectly influencing T-cell responses. Moreover, antigen (Ag)-presenting pDCs directly regulate T-cell differentiation. Depending on the immune environment, pDCs exhibit either tolerogenic or immunogenic properties. Here, we show that CpG-activated pDCs promote efficient Th17 differentiation. Indeed, Th17 responses are defective in mice selectively lacking MHCII on pDCs upon antigenic challenge. Importantly, in those mice, the frequency of Th17 cells infiltrating solid tumors is impaired. As a result, the recruitment of infiltrating leukocytes in tumors, including tumor-specific cytotoxic T lymphocytes (CTL), is altered and results in increased tumor growth. Importantly, following immunization with tumor Ag and CpG-B, MHCII-restricted Ag presentation by pDCs promotes the differentiation of antitumor Th17 cells that induce intratumor CTL recruitment and subsequent regression of established tumors. Our results highlight a new role for Ag presenting activated pDCs in promoting the development of Th17 cells and impacting on antitumor immunity. Cancer Res; 74(22); 6430-40. Ó2014 AACR.
Introduction
Plasmacytoid dendritic cells (pDC) exhibit important innate functions during infections, notably by producing large amount of type I IFN (IFNI; ref. 1). However, recent evidences directly involved these cells in adaptive immunity. pDCs upregulate MHC class II molecules (MHCII) upon inflammation (2) and function as antigen (Ag)-presenting cells (APC) in vivo in several mouse models of diseases to induce both T-cell-mediated immunity and tolerance. For instance, pDCs promote the initiation of myelin-induced Th17 responses and Experimental Autoimmune Encephalomyelitis (EAE; ref. 3) . Furthermore, Ag targeting to pDCs via BST-2 in combination with Toll-like receptor (TLR) agonists provides an effective vaccination (4) . On the other hand, Treg induction by pDCs was shown to delay cardiac allograft rejection, dampen asthmatic reactions to inhaled Ags, and protect against graft versus host disease (5) (6) (7) . In addition, Ag targeting to pDCs via Siglec-H inhibits Th-cell-dependent autoimmunity (8) . We recently formally demonstrated that MHCII-restricted presentation of myelin Ags by pDCs promotes Treg expansion and inhibits EAE (9) .
The role of pDCs in antitumor immunity has been debated. In tumor microenvironment, pDCs exhibit a tolerogenic phenotype characterized by low costimulatory molecule expression and low IFNI production, and promote tumor growth possibly through Treg induction (10) (11) (12) (13) . In contrast, specific Ag delivery to pDCs using BST2 in combination with TLR agonists induced protective immunity against tumor growth (4) . In humans, intranodal injections of pDCs activated and loaded with tumor Ag-associated peptides induced antitumor specific T-cell responses (14) . However, because targeting Ag presentation in pDCs also increased their production of IFNI (15) , those studies could not determine the contribution of Ag presentation by pDCs in impacting tumor T-cell immunity. In addition, TLR-triggered pDCs exhibit potent antitumor effects. Tumor regression has been correlated for some (i.e., R848 and CpG-A), but not all (CpG-B) TLR ligands, with IFNI production by pDCs (16) . Thus, pDC-mediated antitumor potential may rely on other IFNI independent pDC functions, possibly via their ability to present tumor Ags.
Here, we investigated whether Ag-presenting pDC capacities could be modulated and exploited to enhance antitumor T-cell immunity. We show that upon immunization with an Ag and CpG-B, in vivo Ag-specific Th17 responses are significantly impaired in genetically modified mice lacking MHCII expression on pDCs. In contrast with what was shown in conventional DCs (cDC; ref. 17) , MHCII deficiency does not impair innate pDC functions. Importantly, in mice further challenged with tumors, pDC-primed Th17 cells control tumor growth by promoting the recruitment of immune cells, including tumor-specific cytotoxic T lymphocytes (CTL), into the tumors. In addition, vaccination with an MHCII-restricted tumor epitope of mice bearing established tumors significantly induces Th17 cells that promote intratumoral CTL recruitment and tumor growth inhibition, in a mechanism dependent on MHCII expression by pDCs. Thus, CpG-activated pDCs contribute as APCs to the induction of antitumoral Th17 cells that dramatically dampen established tumor growth, a property that may be of interest in the establishment of antitumor immunotherapies.
Materials and Methods

Mice
All mice [WT, H2-Aa À/À (18) , pIIIþIV À/À (19) , OT-I (20),
OT-II Rag2 À/À (21), mMT (22) , mMT pIIIþIV À/À (9)] were of pure C57BL/6 background and maintained under specific pathogen-free conditions. All animal husbandry and experiments were approved by the animal research committee of the University of Geneva (Geneva, Switzerland).
Immunizations and T-cell transfer
Bone marrow (BM) chimeric mice were generated as described (9 
Flow cytometry
Siglec-H (eBio440c), CD8a (53.6.7), TNFa (MP6-XT22), Foxp3 (FJK-16s), CD45.1 (A20), CD3 (145-2C11), and PDCA-1 (eBio927) antibodies were from eBioscience, CD11c (n418), B220 (RA3-6B2), CD19 (6D5), F4/80 (BM8), and CD11b (M1/ 70) antibodies from Biolegend and I-Ab (AF6-120.1), CD4 (RM4.5), IL17 (TC11-18H10), and IFNg (XMG1.2) antibodies from BD. H-2kb SIINFEKL pentamer was purchased from Proimmune.
ELISAs
Cytokine production was assessed in culture supernatants using ELISA Kit from eBioscience (TNFa, IL6, IL17, IL10, and TGFb), BD (IFNg), or PBL (IFNa).
qRT-PCR
Total RNA was isolated and RT-PCR was performed as described (9, 21) . Primer sequences are provided in Supplementary Information.
Dendritic cell isolation from LN
LN cells were isolated (9, 21) , depleted of lymphocytes using CD3 and CD19 antibodies and magnetic sorting (Miltenyi Biotec). pDCs (CD11c int B220
þ PDCA-1 þ ) were sorted using a Moflow Astrios (Beckman Coulter).
Tumor experiments
Mice were immunized subcutaneously with CpG-B (5 mmoles) and OVA II (10 mg) either before (7 days) or after (between 7 days and 10 days) tumor cell transplantation (5 Â 10 5 EG7 thymoma cells, s.c.). Tumor size was measured with a caliper [L (length) Â l (width)]. For tumor-infiltrating lymphocytes (TIL) analysis, tumors were digested with collagenase D (1 mg/mL) þ DNAse 1 (10 mg/mL; Roche) and TILs were enriched using lympholyte M (Cedarlane Laboratory) and restimulated for 18 hours with phorbol 12-myristate 13-acetate (PMA; 50 ng/mL; Sigma) and ionomycine (1 mg/mL; Sigma). When indicated, mice were depleted of CD8 þ T cells using anti-CD8 mAbs (53-6.72), 100 mg i.p. at days 8, 11, and 14 after tumor challenge. In some experiments, EG7 tumor-bearing mice were adoptively transferred with OVA I -specific CD8 þ transgenic T cells (2 Â 10 6 ) purified from LN and spleen of OT-I CD45.1 mice using magnetic sorting (Miltenyi Biotec).
In vitro generation of Th17 cells
OT-II na€ ve T cells were extracted from LN using CD4 þ CD62L þ T cells isolation kit (Miltenyi). Cells were cultured for 3 days on anti-CD3 and anti-CD28 (BioXCell) coated plates in presence with IL6 (25 ng/mL) and TGFb (2.5 ng/mL; eBioscience). Cells (1.10 6 ) were then injected i.v. into sublethally irradiated mice (500 Gy).
In vivo killing assay CFSE labeled splenocytes were loaded (2.5 mmol/L CFSE) or not (0. 5 mmol/L CFSE) with OVA I peptide (SIINFEKL; 10 mg/mL; Polypeptide) and 5 Â 10 6 each (ratio 1:1) was injected i.v. into tumor-bearing mice. Twenty-hours later, CFSE cells were analyzed in tumor dLN (TdLN) and ndLN. Specific in vivo killing was calculated as [1À(% CFSE 2.
Statistical analysis
Statistical significance was assessed by the Mann-Whitney test or by the two-way ANOVA test with Bonferroni correction for tumor growths using GraphPad software. Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.001.
Results
pDCs induce Th17 cells upon CpG-B activation
We investigated whether the lack of MHCII on pDCs has an impact on Th responses upon inflammatory antigenic challenge. MHCII expression is regulated by the master regulator CIITA, itself under the control of cell-specific promoters (Supplementary Fig. S1A ; ref. 23) . MHCII expression in pDCs strictly relies on pIII, whereas pI is expressed in macrophages and cDCs (23 (17) . We tested both in vitro and in vivo whether pDC innate functions could be affected by the loss of MHCII, and explain altered Th17 responses in mice lacking MHCII on pDCs. We first analyzed TLR-triggered responses in pDCs derived in vitro from BM of WT, pIIIþIV Altogether, our data demonstrate that TLR9-activated pDCs act as APCs to induce Th17 cell differentiation.
Tumor Ag presentation by CpG-activated pDCs induces Th17 cells that control subsequent tumor challenge by recruiting immune cells in solid tumors
To determine whether pDC-induced Th17 responses could be exploited in antitumor T-cell immunity, we immunized mMT:WT and mMT pIIIþIV À/À :WT mice with OVA II þ CpG-B and further challenged mice with OVA-expressing tumors (EG7) in the same flank. Mice lacking MHCII on pDCs exhibited a significant increase in tumor growth ( Fig. 3A) , suggesting that OVA II peptide presentation by CpG-activated pDCs controls tumor growth. Similar results were observed when BM chimeric mice were immunized with OVA protein instead of OVA II peptide ( Supplementary  Fig. S5A ), further confirming that pDCs function as bona fide APCs in our model. In addition, we observed a significant reduction in absolute CD45 hi TIL numbers in mMT pIIIþIV À/À :WT compared with mMT:WT mice (Fig. 3B) . Although frequencies of CD4 þ T cells, CD8 þ T cells, cDCs, and pDCs infiltrating solid tumors were identical whether pDCs express MHCII or not, the dramatic reduction of TILs in the absence of MHCII on pDCs led to a significant decrease in absolute numbers of those cells ( Fig. 3C-H ).
To investigate whether tumor growth was controlled by Th17 cells primed by CpG-activated pDCs, we further analyzed effector function of tumor-infiltrating CD4 þ T cells. We observed a significant decrease in frequencies of both IL17 :WT mice, reflecting the drastic reduction in total TILs (Fig. 4C-F) . Consistent with impaired IL17 þ and IL17
þ IFNg þ CD4 þ T-cell frequencies, the production of IFNg and IL17 by TILs was significantly decreased in mice lacking MHCII on pDCs (Fig. 4G ). In contrast, IL10 and TGFb productions were not affected, further confirming that Ag presentation by CpG-activated pDCs did not lead to Treg development (Fig. 4G ). Consistent with a role of tumor-specific Th17 cells in the inhibition of tumor growth, and as described in the mouse B16 melanoma tumor model (26), we observed a significant reduction in tumor size (Fig. 4H) , as well as increased intratumor IL17 cytokine levels (Fig. 4I) , when in vitro differentiated Th17, but not Th0 cells ( Supplementary Fig. S6A and S6B), were adoptively transferred in mice bearing established tumors.
CpG-activated pDC primed Th17 responses promote CTL recruitment in tumors Because tumor rejection is mainly mediated by CTLs, we investigated whether tumor-specific CD8 þ T cells were affect- (Fig. 5C-D) . In dLN, percentages (Fig. 5E-F ) and absolute numbers (not shown) of pentamer CD8 þ T cells were, however, identical in both groups, suggesting an impaired recruitment of those cells in tumors. Moreover, CTL cytotoxic activity was similar whether pDCs express MHCII or not in an in vivo killing assay using OVA I -loaded CFSE-stained target cells ( Fig. 5G and H) . These results suggest that increased tumor-specific Th17 cells induced by CpG-activated pDCs did not alter priming of CTL and Th1 cells in dLN but impaired the recruitment of those cells in solid tumors. Accordingly, total cells isolated from tumor dLN migrated less efficiently toward EG7 tumor supernatant extracted from mMT pIIIþIV
:WT compared with mMT:WT chimeras (Supplementary Fig. S7A ), although relative frequencies of LN cell subsets were not affected (not shown). In addition, the IL17-induced chemokines CCL-2 and CXCL-2 were found significantly decreased in tumor supernatants of mMT pIIIþIV À/À :WT compared with mMT:WT chimeras (Supplementary Fig. S7B) . Altogether, our data demonstrated that CpG-activated pDCs promoted antitumor Th17 cells, intratumoral recruitment of immune cells, including CTLs, and resulted in tumor growth inhibition.
Ag-presenting functions of CpG-activated pDCs can be exploited for antitumor immunotherapies
To determine whether CpG-activated pDC ability to promote antitumor Th17 cells could be used as a therapeutical strategy, we next transferred CpG-activated OVA II -loaded WT or pIIIþIV À/À pDCs in EG7 tumor-bearing mice. Unfortunately, we could not observe any regression of tumors from mice injected with MHCII sufficient pDCs (not shown). Similarly, the vaccination of mice bearing established tumors with OVA II þ CpG-B had no beneficial effect on tumor growth when performed in the flank in which the tumor developed (not shown), suggesting that pDC ability to prime effector T cells might have been altered by the tumor microenvironment. However, contralateral OVA II þ CpG-B vaccination led to a significant reduction in tumor size (Fig. 6A ). In addition, we observed similar results when tumor-bearing mice were immunized with OVA protein þ CpG-B (Supplementary Fig. S5B ). Importantly, tumors from OVA II þ CpG-B vaccinated mice exhibited a dramatic increase in infiltrating CD45 hi TILs, with a selective enrichment of Th17 cells (Fig. 6B-E) . In agreement, IL17 produced at the vaccination site, and consequently in tumors was significantly increased (Fig. 6F) . These data show that OVA II þ CpG-B vaccination of tumor-bearing mice promotes Th17 cells that induce intratumor cell recruitment and tumor growth inhibition. Consistent with our previous observations, vaccination did not affect tumor-specific CTL frequencies (Fig. 6G-I) . However, as a consequence of enhanced cell infiltration, absolute numbers of Th1, Th17, pentamer
and IFNg-producing CD8 þ T cells were significantly increased (Fig. 6C, D , and G-I).
To determine whether tumor growth inhibition observed following vaccination of tumor-bearing mice was dependent on MHCII-mediated Ag presentation by pDCs, we performed similar experiments in mMT:WT and mMT pIIIþIV tumor growth inhibition, whereas, in contrast, no protective effect was observed in mMT pIIIþIV À/À :WT, in which pDCs are MHCII deficient (Fig. 6J) . Altogether, these results demonstrate that OVA II þCpG-B mediated tumor regression, and that this effect was dependent on pDC Ag-presenting functions.
Antitumor adaptive immune responses against EG7 tumors are mainly CTL-dependent (27) (28) (29) . To determine whether Th17-mediated control of tumor growth was CTL dependent, CD8
þ T cells were depleted in WT tumor-bearing mice vaccinated or not with OVA II þ CpG-B. As expected, CD8 depletion led to a significant increase in tumor size (Fig. 7A) . Importantly, we observed a total abrogation of OVA II þ CpG-B vaccine efficacy in the absence of CD8 þ T cells (Fig. 7A) , suggesting that OVA II -mediated Th17 cells control tumor growth in a CD8-dependent manner. Most of the cancer therapies and vaccines developed so far have been directed to target specific CD8 þ T cells (30) . Thus, we next wondered whether having a concomitant antitumor Th17 and CD8 T-cell responses improve tumor rejection. For that we adoptively transferred OT-I cells into WT EG7 tumor-bearing mice that we vaccinated or not with OVA II þ CpG-B. We injected suboptimal OT-I amounts (2 Â 10 6 ), which only conferred a partial and time-limited control of tumor growth when transferred alone (Fig. 7B) . OVA II þ CpG-B vaccination increased OT-I recruitment into tumors (Fig. 7C) , and consequently significantly ameliorated and prolonged OT-1-mediated tumor growth inhibition (Fig. 7B) . Accordingly, OVA II þ CpG-B vaccination dramatically improved OT-1-mediated tumor rejection in mMT:WT chimeras (Fig. 7D) . In striking contrast, OVA II þ CpG-B vaccination had no effect on tumor growth in OT-I transferred mMT pIIIþIV À/À :WT (Fig. 7D) , highlighting the importance of Ag presentation by pDCs in this model.
Altogether, our results demonstrate that antitumor vaccination using MHCII-restricted epitopes in the presence of CpG-B induce tumor antigen presentation by pDCs and subsequent antitumor Th17 responses. pDC-mediated Th17 cells consequently potentialize CTL-mediated tumor immunotherapies by increasing intratumor CTL recruitment.
Discussion
pDCs are potent sensors of nucleic acid and become activated to produce large amounts of IFNI (31) . Those cells, despite low Ag uptake capacity, also function as APCs in several conditions and, depending on their activation status and the cytokinic environment, promote either T-cell tolerance (3, 4) or effective T-cell immunity (5-9). In tumors, it has been demonstrated that IFNI displays antitumoral effects through antiproliferative and proapoptotic functions, thus inhibiting tumor cells survival and angiogenesis (32, 33) . Moreover, IFNI 
and IFNg þ CD8 þ T cells (I). F, IL17 was measured in culture supernatants. limits tumor progression by enhancing CD8a þ DCs mediated cross-presentation of tumor Ags and subsequent CTL priming (34, 35) . Consequently, IFNIs are used in the treatment of various cancers (32) . However, pDC ability to produce IFNI is impaired in tumor microenvironment, therefore converting these cells into tolerogenic pDCs and leading to immunosuppression in several different cancers (for review, see ref. 33 ).
In addition, in breast tumors in particular, pDCs induce Treg expansion in IDO and/or ICOS-dependent mechanisms (10) (11) (12) . Accordingly, pDC infiltration in tumors has been correlated with poor clinical outcome (36, 37) . Thus, promoting pDC activation in tumor context would restore IFNI production, inhibit Treg expansion, and represent an effective approach to induce antitumoral immune response. In agreement, CpG-A-activated, IFNI-producing pDCs injected directly into tumors initiate an effective and systemic antitumor immunity through the orchestration of an immune cascade involving the sequential activation of natural killer (NK) cells, cDCs, and CD8 þ T cells (38) . Moreover, TLR7 ligands or CpG-B intratumoral injection inhibit murine mammary tumor growth in a pDC-dependent manner (16) . Interestingly, however, protection was linked to restoration of IFNI occurring after TLR7 ligand, but not after CpG-B, administration. Thus, although the role of pDCmediated IFNI in antitumor immunity has been convincingly demonstrated, it remains unknown whether those cells could directly contribute to antitumoral T-cell immunity as APCs, and in particular after being activated by CpG-B.
Here, using mice lacking MHCII expression by pDCs, we show that upon CpG-B activation, pDCs drive Th17 cell differentiation through MHCII-dependent Ag presentation. For experimental reasons, our mouse model lacks peripheral B cells, which might not be neutral. However, we compared MHCII þ and MHCII À pDCs in a B-cell deficient background, and investigated the selective impact of MHCII-mediated Ag presentation by pDCs on CD4 þ T-cell responses and tumor growth. It has been previously demonstrated that TLR triggered pDCs indirectly impact T-cell responses by activating other APCs (1). Our results, together with previous studies, highlight a direct role for pDCs as APCs in the modulation of T-helper activation and outcome. Our data further establish that, in contrast with what was described for cDCs, innate pDC functions are not altered by the loss of MHCII. Because MHCII machinery is differentially regulated in pDCs and cDCs (39, 40) , regulation of TLR-triggered inflammatory responses may also be different in those cells, and, in contrast with cDCs (17), MHCII may not promote TLR signaling in pDCs. Altogether, our data demonstrate that loss of MHCII expression by pDCs leads to impaired Th17 responses without affecting pDC innate functions and that CpG-activated pDCs function as efficient pro-Th17 bona fide APCs. Tissue infiltrating pDC numbers were correlated with the presence of Th17 cells in mucosa and skin of GvHD patients (41, 42) and in mouse tumors (43, 44) . pDC depletion during EAE leads to impaired encephalitogenic Th17 responses and decreased clinical scores (3). In vitro, pDCs activated with TLR7 or TLR9 ligands induce Th17 cell differentiation from either naive or memory T cells (45, 46) . In addition, TGFb-treated pDCs transferred into collagen-induced arthritis mice promote Th17 cells and exacerbate the disease (47) . Depleting antibody experiments demonstrated that production of some cytokines by pDCs, namely TGFb, IL6, IL1b, IL23, IFNa, and TNFa depending on the studies, was involved in Th17 cell differentiation (44, 46, 47) . We clearly determined that, in addition to pDC-derived cytokines that are preserved in our model, pDC Ag-presenting capacities are implicated in Th17 induction. However, mechanisms accounting for CpG-B-activated pDC ability to drive Th17 cells as APCs remain to be elucidated. Future experiments, including careful analysis of protein expression and dynamic interactions with T cells, will decipher intrinsic pDC properties, which allow them to promote distinct T-cell responses (Th1, Th17, Treg) depending on inflammatory contexts.
Subsequent tumor cell challenge showed that pDC-primed Th17 cells control tumor growth. Moreover, our data suggest that pDC-induced Th17 and Th1/17 cells promote inflammation and intratumor recruitment of immune cells, including Ag-specific CTLs, resulting in an increased antitumor immunity. Th17 cells implication in tumor immunity remains controversial. For instance, IL17 production favors angiogenesis and tumor cell survival (48, 49) . Conversely, Th17 might improve tumor rejection by recruiting other immune cells such as DCs, Th, CTLs, and NK cells in the tumor (50) (51) (52) . Accordingly, the IL17-induced CCL-2 and CXCL-2 chemokines, were decreased in tumor supernatants from mice lacking MHCII on pDCs. Decrease in CCL-2 and CXCL-2, which induce the recruitment of lymphocytes, myeloid cells (53) (54) (55) , and neutrophils (56) , respectively, may explain impaired recruitment of several immune cell populations into tumors in mice lacking MHCII on pDCs. Altogether, our data demonstrated that MHCII þ pDC-derived, tumor-specific Th17 cells increase overall immune tumor infiltrate, including CTLs that would then mediate tumor rejection. Finally, and in agreement with our results showing a decrease in IFNg þ IL17 þ Th cells in absence of MHCII on CpG-activated pDCs, production of IFNg by Th17 cells was shown to be essential for Th17-dependent tumor rejection (26) . Tumor microenvironment maintains pDCs in a partially activated phenotype that would prevent their ability to drive effective antitumor T-cell responses (10) . Accordingly, in tumor-bearing mice, immunization with a tumor Ag in presence of CpG-B in an ipsilateral manner, or transfer of CpG-B activated and tumor Ag-loaded pDCs, failed to inhibit tumor growth. However, tumor Ag immunization at a distal site leads to induction of tumor-specific Th17 cells, massive recruitment of immune cells in tumors, and inhibition of tumor growth. Importantly, those protective effects are abrogated in mice lacking MHCII on pDCs, demonstrating requirement of pDC Ag-presenting functions for effective tumor regression. Interestingly, efficacy of therapeutic vaccines was more potent than in a prevention setting. One probable explanation is that when the vaccine is administrated to tumor-bearing mice, tumor-specific CTLs have already been primed, and as soon as some vaccine-derived Th17 cells are induced, and infiltrate solid tumors to promote intratumor recruitment of already primed endogenous tumor-specific CTLs. In contrast, in the case of preventive vaccine, Th17 cells are primed in the absence of any MHCI tumor Ags and consequently attract CTLs only once they have been generated, days after tumor challenge. OVA II vaccine-induced protection is abrogated in CD8-depleted mice, providing direct evidence that pDC-mediated Th17-induced tumor rejection relies on tumor-specific CTLs.
Notably, intratumoral specific CTL recruitment, as well as CTL-mediated tumor rejection, is significantly enhanced by concomitant vaccination with MHCII-restricted tumor Ag and CpG-B. Importantly, this effect is exclusively dependent on tumor Ag presentation by pDCs to CD4
þ T cells and subsequent induction of antitumor Th17 responses. Thus, strategies aiming at enhancing tumor-specific CTL priming, such as MHCI tumor epitope vaccines, could be synergized by promoting CTL recruitment into tumors via induction of pDCdependent tumor-specific Th17.
Here, we demonstrate that Ag-presenting activated pDCs induce potent Ag-specific Th17 cells, suggesting that pDCs could be used not only as inflammatory cytokines producers, but also as efficient APCs, to improve tumor vaccine efficacy. Those results pave the way for future manipulation to restore the antitumor T-cell responses, notably by combining targeting on both innate and adaptive pDCs functions.
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